Can Anemia Be a Confounder in Nt-Probnp Interpretation?
DOI:
https://doi.org/10.56981/Keywords:
Hemoglobin, NT-Probnp, Heart Failure, Anemia, Cardiomyocytes.Abstract
Heart failure is a major clinical issue of concern worldwide. Many biomarkers are used to aid the diagnosis of heart failure patients. One of the increasingly used biomarkers is the biologically inactive NT-proBNP. Several confounding factors affect plasma NT-proBNP levels, and hence, the validity of its interpretation. Heart failure and anemia are well correlated, as evidenced by variety of studies. In, anemia can yield some degree of cardiac stress that leads to the expression of NT-proBNP levels above the cut-off values.
This study aimed to test whether anemia can be associated with an elevated peptide level in patients without heart failure. A cross-sectional study in which a total of 108 randomly selected patients, irrespective of their hemoglobin levels, were recruited. Males comprised 39.8% of the total, and the patients were divided based on their hemoglobin levels into anemic (55 patients) and non-anemic (53 patients) groups. Plasma NT-proBNP levels were assessed using ELISA, and the results were interpolated and analyzed against hemoglobin levels. The NT-proBNP level was significantly higher in patients with anemia (p < .0001) where it was 268.7 ± 38.9 vs. 93.55 ± 17.4 ng/dl for both the anemic and non-anemic groups, respectively. Hemoglobin level showed a negative correlation with plasma peptide level ([F (1, 107) = 28.63, p < .0001)], with an r2 of 0.358.
Anemia is inversely correlated with the plasma NT-proBNP level. In fact, anemia can raise the peptide level beyond its recommended cutoff levels making the interpretation of the raised NT-proBNP more challenging.
References
1. Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. Journal of Biological Engineering. 2018;12(1):2.
2. Liu H-H, Cao Y-X, Jin J-L, Guo Y-L, Zhu C-G, Wu N-Q, et al. Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective cohort study. Cardiovascular Diabetology. 2021;20(1):84.
3. Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest. 2014;44(3):303-8.
4. Parcha V, Patel N, Kalra R, Suri SS, Arora G, Wang TJ, et al. Obesity and Serial NT‐proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE‐IT Trial. Journal of the American Heart Association. 2021;10(7):e018689.
5. Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, et al. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clinical Research in Cardiology. 2020;109(3):331-8.
6. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. Int J Mol Sci. 2019;20(8):1820.
7. Cappellini MD, Motta I. Anemia in Clinical Practice-Definition and Classification: Does Hemoglobin Change With Aging? Semin Hematol. 2015;52(4):261-9.
8. Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure. Circulation. 2018;138(1):80-98.
9. Bird JG, Morant K, Al-Souri D, Scott CG, Padang R, McCully RB, et al. Impact of Anemia on Exercise and Pharmacologic Stress Echocardiography. J Am Soc Echocardiogr. 2020;33(9):1067-76.
10. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330-7.
11. Willis MS, Lee ES, Grenache DG. Effect of anemia on plasma concentrations of NT-proBNP. Clin Chim Acta. 2005;358(1-2):175-81.
12. Tirmenstajn-Jankovic B, Dimkovic N, Perunicic-Pekovic G, Radojicic Z, Bastac D, Zikic S, et al. Anemia is independently associated with NT-proBNP levels in asymptomatic predialysis patients with chronic kidney disease. Hippokratia. 2013;17(4):307-12.
13. Tominaga M, Kawai M, Minai K, Ogawa K, Inoue Y, Morimoto S, et al. Association between plasma B-type natriuretic peptide and anaemia in heart failure with or without ischaemic heart disease: a retrospective study. BMJ Open. 2019;9(3):e024194.
14. Abebe TB, Gebreyohannes EA, Bhagavathula AS, Tefera YG, Abegaz TM. Anemia in severe heart failure patients: does it predict prognosis? BMC Cardiovascular Disorders. 2017;17(1):248.
15. Díez-López C, Lupón J, de Antonio M, Zamora E, Domingo M, Santesmases J, et al. Hemoglobin Kinetics and Long-term Prognosis in Heart Failure. Revista Española de Cardiología (English Edition). 2016;69(9):820-6.
16. Anand IS, Rector TS. Pathogenesis of Anemia in Heart Failure. Circulation: Heart Failure. 2014;7(5):699-700.
17. Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in Heart Failure: Still Relevant? JACC: Heart Failure. 2018;6(3):201-8.
18. Buckley LF, Canada JM, Del Buono MG, Carbone S, Trankle CR, Billingsley H, et al. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Fail. 2018;5(2):372-8.
19. Ahn JH, Jeon J, Toh HC, Noble VE, Kim JS, Kim YS, et al. SEARCH 8Es: A novel point of care ultrasound protocol for patients with chest pain, dyspnea or symptomatic hypotension in the emergency department. PLoS One. 2017;12(3):e0174581.
20. Zhang B, Xu H, Zhang H, Liu Q, Ye Y, Hao J, et al. Prognostic Value of N-Terminal Pro–B-Type Natriuretic Peptide in Elderly Patients With Valvular Heart Disease. Journal of the American College of Cardiology. 2020;75(14):1659-72.
21. Januzzi James L, Myhre Peder L. The Challenges of NT-proBNP Testing in HFpEF. JACC: Heart Failure. 2020;8(5):382-5.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 https://creativecommons.org/licenses/by/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
